In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...
Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion on new therapies and the role of diet.
For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines, ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.
Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...
A new groundbreaking study revealed that Remibrutinib showed promising results in treating chronic spontaneous urticaria.A recent study published in the New England Journal of Medicine outlined the ...
The advent of remibrtuinib, a Bruton's tyrosine kinase inhibitor, may encourage dermatologists to take care of chronic spontaenous urticaria patients, says a presenter at the 2025 meeting of the ...
Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback